BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25786478)

  • 1. Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.
    Farrukee R; Leang SK; Butler J; Lee RT; Maurer-Stroh S; Tilmanis D; Sullivan S; Mosse J; Barr IG; Hurt AC
    J Antimicrob Chemother; 2015 Jul; 70(7):2004-12. PubMed ID: 25786478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
    Takashita E; Meijer A; Lackenby A; Gubareva L; Rebelo-de-Andrade H; Besselaar T; Fry A; Gregory V; Leang SK; Huang W; Lo J; Pereyaslov D; Siqueira MM; Wang D; Mak GC; Zhang W; Daniels RS; Hurt AC; Tashiro M
    Antiviral Res; 2015 May; 117():27-38. PubMed ID: 25721488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
    Fujisaki S; Imai M; Takashita E; Taniwaki T; Xu H; Kishida N; Yokoyama M; Sato H; Tashiro M; Odagiri T
    J Infect Chemother; 2013 Oct; 19(5):891-5. PubMed ID: 23529501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
    Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
    Brown SK; Tseng YY; Aziz A; Baz M; Barr IG
    Antiviral Res; 2022 Apr; 200():105280. PubMed ID: 35304163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.
    Pascua PNQ; Marathe BM; Bisen S; Webby RJ; Govorkova EA
    Antiviral Res; 2020 Jan; 173():104669. PubMed ID: 31790712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.
    Wang D; Sleeman K; Huang W; Nguyen HT; Levine M; Cheng Y; Li X; Tan M; Xing X; Xu X; Klimov AI; Gubareva LV; Shu Y
    Antiviral Res; 2013 Mar; 97(3):240-4. PubMed ID: 23267831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
    Mohr PG; Williams J; Tashiro M; Streltsov VA; McKimm-Breschkin JL
    Antiviral Res; 2020 Oct; 182():104895. PubMed ID: 32750469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Susceptibility of Influenza B Viruses to Neuraminidase Inhibitors Isolated during 2013-2014 Influenza Season in Mainland China].
    Huang W; Li X; Tan M; Wei H; Cheng Y; Guo J; Wang Z; Xiao N; Wang D; Shu Y
    Bing Du Xue Bao; 2015 Mar; 31(2):152-6. PubMed ID: 26164940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
    van der Vries E; Ip DK; Cowling BJ; Zhang JD; Tong X; Wojtowicz K; Schutten M; Boucher CA
    J Infect Dis; 2016 Jan; 213(2):183-90. PubMed ID: 26160744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
    Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D
    J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.
    Burnham AJ; Baranovich T; Marathe BM; Armstrong J; Webster RG; Govorkova EA
    Antimicrob Agents Chemother; 2014 May; 58(5):2718-30. PubMed ID: 24566185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
    Little K; Leang SK; Butler J; Baas C; Harrower B; Mosse J; Barr IG; Hurt AC
    Euro Surveill; 2015; 20(45):. PubMed ID: 26608955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
    Gubareva LV
    Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
    Fage C; Tu V; Carbonneau J; Abed Y; Boivin G
    Antivir Ther; 2017; 22(8):711-716. PubMed ID: 29082897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.